Introduction {#sec1}
============

Sjögren's syndrome (SS) is a systemic autoimmune disease characterized by lymphocytic infiltration of the exocrine glands, predominantly the salivary and lacrimal glands \[[@cit0001]\]. Global worldwide prevalence is 0.06% and it predominantly affects females \[[@cit0002]\]. Oral and ocular dryness are primary clinical features which are caused by functional impairment of salivary and lacrimal glands. However, extra-glandular involvement may develop during disease progression and most patients complain of subjective symptoms such as arthralgia, myalgia and fatigue \[[@cit0003], [@cit0004]\]. In addition, several psychological disorders such as anxiety and depression are more prevalent in pSS patients than in the healthy controls \[[@cit0005]--[@cit0007]\]. Sjögren's syndrome is associated with working disability, general discomfort and decreased health-related quality of life (HRQOL) \[[@cit0008]--[@cit0012]\]. As treatment of SS is symptom oriented, HRQOL assessment is important to be able to understand the disease activity, and select the appropriate therapy \[[@cit0013]\].

The European League Against Rheumatism (EULAR) SS study group recently developed two major outcome tools to measure disease activity and patient reported symptoms: the EULAR Sjögren's syndrome disease activity index (ESSDAI) for systemic features and severity and the EULAR Sjögren's syndrome patient reported index (ESSPRI) for the measurement of patients' symptoms \[[@cit0014], [@cit0015]\]. These two instruments have been validated and shown to be sensitive to change \[[@cit0016]\].

There are various studies in the literature that have focused on fatigue, anxiety, depression, oral HRQOL and general HRQOL \[[@cit0012], [@cit0013], [@cit0017], [@cit0018]\]. However, to the best of our knowledge, there are very few studies investigating the relationship between the pSS specific outcome measures (ESSPRI and ESSDAI) and HRQOL \[[@cit0019], [@cit0020]\]. The aim of this study was to investigate whether there is a relationship between the EULAR outcome measures and quality of life (QoL), fatigue, anxiety and depression in patients with primary Sjögren's syndrome (pSS) and to define determinants which could affect quality of life.

Material and methods {#sec2}
====================

Patients {#sec2.1}
--------

A total of 105 consecutive pSS patients who met the 2002 American-European Consensus Group (AECG) criteria for diagnosing PSS \[[@cit0021]\] and were being followed up at the rheumatology outpatient clinics of 3 hospitals in Turkey were enrolled in this multicentre, cross-sectional study. The control group was formed of 72 age- and gender-matched healthy individuals. Exclusion criteria were patients with known psychiatric disease, fibromyalgia, comorbid chronic diseases, such as hyperthyroidism, hypothyroidism, diabetes mellitus, and malignancies, age \< 18 years or inability to give written informed consent. The statistical power was set to be 95% and the type 1 error rate was set to be 5%. According to the results of the analysis, the sample size for each group to be suitable for analysis was 71 individuals.

The study was approved by the Ethics Committee of Yildirim Beyazit University Medical School and written informed consent was obtained from all participants according to the principles of the Helsinki Declaration. The demographic, clinical and laboratory data of the patients were recorded.

Fatigue was assessed using the Multidimensional Assessment of Fatigue scale (MAF). This self-reported questionnaire contains 16 items and measures four dimensions of fatigue: severity, distress, timing and degree of interference with daily living activities. The MAF score ranges from 0 to 50 and higher scores indicate higher levels of fatigue \[[@cit0022]\].

Anxiety and depression were assessed with the Hospital Anxiety and Depression Scale (HADS). This self-evaluation questionnaire consists of 2 subscales: anxiety (HADS-A) and depression (HADS-D). Both subscales contain 7 items and each item is scored from 0 to 3. HADS scores of 8--10 define possible, scores of 11--14 define probable and scores of 15--21 define extreme cases of depression and anxiety \[[@cit0023]\].

Quality of life was assessed with a validated Turkish translation of the 36-item Short Form (SF-36) \[[@cit0024]\]. The SF-36 is a questionnaire for self-evaluation of the prior 1 month. It consists of eight health-related domains including physical functioning (PF, 10 items), role-physical (RP, 4 items), bodily pain (BP, 2 items), general health (GH, 5 items), vitality (VT, 4 items), social functioning (SF, 2 items), mental health (MH, 5 items), and role-emotional (RE, 3 items). Based on these separate domains, physical (PCS) and mental component summary scores (MCS) are calculated. Each domain and summary score ranges from 0 to 100, with higher scores indicating a better quality of life \[[@cit0025]\].

The ESSPRI is a self-evaluation index for measuring symptoms including pain, fatigue and dryness. Each symptom was measured with a single 0 (no symptoms) to 10 (severe symptoms) numerical scale and the final ESSPRI score is calculated by averaging these domains with a maximum severity score of 10. Scores of \< 5 indicate low disease activity and scores of ≥ 5 indicate high disease activity \[[@cit0015], [@cit0026]\].

The EULAR SS disease activity index (ESSDAI) is a physician-based assessment of the systemic features and severity of the disease and includes 12 domains (constitutional, lymphadenopathy, glandular, articular, cutaneous, respiratory, renal, muscular, peripheral nervous system, central nervous system, hematological, biological). ESSDAI ranges from 0 to 123. ESSDAI \< 5 is defined as low disease activity, 5 ≤ ESSDAI ≤ 13 is defined as moderate disease activity and ESSDAI ≥ 14 is defined as high disease activity \[[@cit0014], [@cit0026]\].

Statistical analysis {#sec2.2}
--------------------

All data were analyzed using the Statistical Package for Social Sciences (SPSS Inc., Chicago, IL, USA) 16.0 program for Windows. The variables were investigated using visual and analytical methods to determine whether they were normally distributed. Normally distributed continuous values were expressed as mean ± standard deviation (SD) and categorical variables as number and percentage. Non-normally distributed parameters were reported as median values with inter-quartile range (IQR) (25^th^ and 75^th^ percentiles). Student's *t*-test was used for comparison of normally distributed data, and the Mann-Whitney *U* test, Wilcoxon rank test and Kruskal-Wallis test were used for comparison of non-normally distributed data. The χ^2^ test was used for categorical variables. Pearson's correlation coefficient and Spearman's correlation coefficient were used to evaluate the linear relationship between the predictive variables. A value of *p* \< 0.05 was considered statistically significant. Multivariate linear regression analysis using the stepwise method was performed to determine the variables independently associated with SF-36 scores.

Results {#sec3}
=======

The demographic and clinical features of pSS patients are shown in [Table I](#t0001){ref-type="table"}. Forty-nine (46.7%) patients had low disease activity (ESSDAI \< 5), 45 (42.9%) had moderate disease activity (5 ≤ ESSDAI ≤ 13), and 11 (10.5%) had high disease activity (ESSDAI ≥ 14). Fifty-five (52.4%) patients had ESSPRI \< 5 and 50 (47.6%) had ESSPRI ≥ 5.

###### 

Demographic and clinical characteristics of the pSS patients (n = 105)

  Variables                                          Result
  -------------------------------------------------- ----------------
  Age \[years\]                                      44 ±10.5
  Gender (female)                                    97 (92.4%)
  Age at time of diagnosis \[years\]                 41.5 ±10.0
  Disease duration \[years\]                         2.1 ±1.8
  Ocular symptoms                                    99 (94.2%)
  Oral symptoms                                      96 (91.4%)
  Schirmer test ≤ 5 mm/5 min                         87 (82.8%)
  Positive salivary gland biopsy (focus score ≥ 1)   93/81 (87.1%)
  Autoantibodies:                                    
   Anti-Ro (SSA)                                     77/100 (77%)
   Anti-La (SSB)                                     51/100 (51%)
   ANA titer \> 1/160                                83/103 (80.6%)
   RF                                                37/102 (36.3%)
  CRP \[mg/l\]                                       3.4 (1--3.9)
  ESR \[mm in first h\]                              20 (12--34)
  Disease activity indexes:                          
   ESSDAI                                            5 (2--9.5)
   ESSPRI                                            4.6 (3--6)
  Current treatment:                                 
   Corticosteroids                                   26 (24.7%)
   Hydroxychloroquine                                85 (80.9%)
   Azathioprine                                      7 (6.6%)
   Methotrexate                                      15 (14.2%)
   Rituximab                                         5 (4.7%)
   Pilocarpine                                       10 (9.5%)
   Lachrymal substitute                              80 (76%)
   Non-steroidal anti-inflammatory drug              40 (38%)
   Without treatment                                 9 (8.5%)

Results are expressed as median (IQR)\], mean ± SD or number (%), where appropriate. ANA -- antinuclear antibodies, RF -- rheumatoid factor, CRP -- C-reactive protein, ESR -- erythrocyte sedimentation rate, ESSDAI -- EULAR Sjögren's syndrome disease activity index, ESSPRI -- EULAR Sjögren's syndrome patient reported index, EULAR -- European League Against Rheumatism.

Age, gender, depression, anxiety, fatigue scores, SF-36 summary scores (PCS, MCS) and laboratory parameters of the patients and the healthy controls are presented in [Table II](#t0002){ref-type="table"}. HADS-D (*p* = 0.002), HADS-A (*p* \< 0.001), MAF (*p* = 0.013) scores and erythrocyte sedimentation rate (ESR) (*p* \< 0.001) were significantly higher in pSS patients than in the control group, while SF-36 summary scores ((PCS, MCS) (*p* = 0.01, *p* \< 0.001)) were lower than those of the control group. In the assessment of SF-36 subgroup scores, all items, particularly role-physical (RP) and role-emotional, were observed to be statistically lower in pSS patients than in the control group ((*p* = 0.006) for vitality, (*p* \< 0.001) for items other than vitality) ([Figure 1](#f0001){ref-type="fig"}). Of the 105 pSS patients, 17.1% were scored as possible, 11.4% as probable and 1% as extreme cases of depression and 23.8% were scored as possible, 15.2% as probable and 5.7% as extreme cases of anxiety. If the cut-off value was considered as 8 in HADS, anxiety was found to be significantly higher in pSS patients than in the control group (47 (44.8%) vs. 21 (38.4%), *p* = 0.036). The frequency of depression was higher in pSS patients (31 (29.5%) vs. 17 (23.6%)), but the difference was not statistically significant (*p* = 0.385).

###### 

Age, gender, depression (HADS-D), anxiety (HADS-A), fatigue (MAF), SF-36 summary scores (PCS, MCS) and laboratory parameters of pSS patients and HCs

  Variables       pSS (*n* = 105)   HC (*n* = 72)   *P*-value
  --------------- ----------------- --------------- -----------
  Age \[years\]   44 ±10.5          44.3 ±6.9       NS
  Gender (F/M)    97/8              62/10           NS
  HADS-D          6.7 ±2.8          5.1 ±3.5        0.002
  HADS-A          7.6 ±3.6          5.4 ±3.3        \< 0.001
  MAF             21.7 ±9.1         18.5 ±7.3       0.013
  PCS             42.6 ±5.5         47.1 ±5.8       0.01
  MCS             40.0 ±6.6         48.8 ±7.9       \< 0.001
  ESR \[mm/h\]    20 (12--33.5)     8 (5--12.7)     \< 0.001
  CRP \[mg/l\]    3.4 (1--3.5)      2 (1--4)        NS

ESR and CRP are shown as median values (IQR). Other variables are stated as mean ± SD. NS -- non-significant, HADS-D -- Hospital Anxiety and Depression Scale-depression, HADS-A -- Hospital Anxiety and Depression Scale-anxiety, MAF -- Multidimensional Assessment of Fatigue, PCS -- physical component summary scores, MCS -- mental component summary scores, ESR -- erythrocyte sedimentation rate, CRP -- C-reactive protein.

![SF-36 subscale scores of pSS patients and HCs\
PF -- physical functioning, RP -- role-physical, BP -- bodily pain, GH -- general health, VT -- vitality, SF -- social functioning, RE -- role-emotional, MH -- mental health;\
\*p \< 0.001, \*\*p = 0.006](AMS-14-30678-g001){#f0001}

The SF-36, HADS-D, HADS-A and MAF scores of the pSS patients according to disease activity are shown in [Table III](#t0003){ref-type="table"}. When the disease activity was assessed with ESSDAI, except MH all the SF-36 scores of patients with low disease activity were significantly higher than those of patients with moderate and high disease activity. Only the BP, GH, SF, PCS and MCS scores of patients with moderate disease activity were significantly higher than those of patients with high disease activity. Patients with higher ESSDAI scores tended to have higher HADS-A, HADS-D and MAF scores without reaching statistical significance. According to the ESSPRI, except SF and MH, all SF-36 scores were significantly lower and HADS-A, HADS-D and MAF scores were significantly higher in the active group.

In correlation analysis, a positive correlation between ESSDAI and ESSPRI was detected (*r* = 0.31, *p* \< 0.001). Correlation analysis of pSS patients between SF-36 scores, fatigue, anxiety, depression and EULAR Sjögren's syndrome outcome measures is shown in [Table IV](#t0004){ref-type="table"}. ESSDAI was positively correlated with fatigue score (*r* = 0.26, *p* = 0.003) and negatively correlated with PCS and MCS scores (*r* = --0.32, *p* \< 0.001, *r* = --0.50, *p* \< 0.001 respectively). ESSPRI showed a positive correlation with fatigue, anxiety and depression (*r* = 0.80, *r* = 0.58, *r* = 0.49 all *p* \< 0.001 respectively) and a negative correlation with PCS and MCS (*r* = --0.69, *r* = --0.26 and all *p* \< 0.001 respectively). The MAF score was positively correlated with HADS-A and HADS-D scores (*r* = 0.57, *p* \< 0.001, *r* = 0.50, *p* \< 0.001, respectively). The HADS-A score was positively correlated with the HADS-D score (*r* = 0.62, *p* \< 0.001).

###### 

SF-36, HADS-D, HADS-A and MAF scores of pSS patients according to disease activity

  Variable   ESSDAI         ESSPRI                                                                                                            
  ---------- -------------- ------------- ------------- -------------- -------------- -------------- ----------- ------------- -------------- --------------
  PF         47.35 ±6.59    43.66 ±5.77   39.71 ±5.87   **\< 0.001**   **\< 0.001**   **\< 0.001**   0.064       46.06 ±5.44   42.96 ±7.80    **0.015**
  RP         46.87 ±8.53    41.26 ±8.23   42.08 ±6.86   **\< 0.001**   **\< 0.001**   **0.006**      0.671       46.21 ±6.62   40.20 ±10.01   **\< 0.001**
  BP         46.95 ±7.33    44.10 ±7.73   38.78 ±8.54   **\< 0.001**   **0.031**      **0.002**      **0.031**   47.74 ±5.98   40.14 ±8.60    **0.005**
  GH         46.66 ±8.05    41.69 ±7.47   38.55 ±3.83   **\< 0.001**   **\< 0.001**   **\< 0.001**   **0.042**   46.76 ±6.43   38.56 ±7.55    **\< 0.001**
  VT         49.02 ±5.35    46.82 ±7.00   43.74 ±6.41   **0.004**      **0.026**      **0.002**      0.142       49.29 ±4.59   44.58 ±7.73    **\< 0.001**
  SF         43.96 ±8.35    41.14 ±8.70   31.56 ±6.57   **\< 0.001**   **0.047**      **\< 0.001**   **0.001**   42.99 ±7.17   38.65 ±11.00   0.663
  RE         44.62 ±10.29   37.84 ±9.49   31.40 ±9.05   **\< 0.001**   **\< 0.001**   **\< 0.001**   0.057       42.22 ±8.97   36.86 ±12.38   **0.014**
  MH         39.31 ±7.83    37.89 ±6.30   36.03 ±3.65   0.135          0.225          0.056          0.284       39.07 ±6.11   37.12 ±7.77    0.289
  PCS        48.44 ±6.71    44.10 ±6.46   41.98 ±5.17   **\< 0.001**   **\< 0.001**   **\< 0.001**   **0.026**   48.87 ±4.33   41.02 ±7.34    **\< 0.001**
  MCS        42.29 ±5.95    39.43 ±6.56   33.68 ±5.36   **\< 0.001**   **0.002**      **\< 0.001**   **0.003**   41.16 ±4.88   38.30 ±8.53    **0.002**
  HADS-A     7.22 ±3.70     8.11 ±3.82    8.00 ±2.72    0.365          0.215          0.303          0.819       6.22 ±2.23    9.30 ±4.23     **\< 0.001**
  HADS-D     6.61 ±3.10     6.84 ±2.66    7.09 ±2.51    0.777          0.600          0.563          0.721       6.04 ±2.36    7.56 ±3.12     **0.001**
  MAF        19.63 ±8.99    23.85 ±9.20   22.39 ±7.80   0.067          0.024          0.248          0.695       16.89 ±6.70   27.05 ±8.47    **\< 0.001**

Values are presented as mean ± SD. ESSDAI -- EULAR Sjögren's syndrome disease activity index, ESSPRI -- EULAR Sjögren's syndrome patient reported index, EULAR -- European League Against Rheumatism, MAF -- Multidimensional Assessment of Fatigue, HADS-A -- Hospital Anxiety and Depression Scale-anxiety, HADS-D -- Hospital Anxiety and Depression Scale-depression, PF -- physical functioning, RP -- role-physical, BP -- bodily pain, GH -- general health, VT -- vitality, SF -- social functioning, RE -- role-emotional, MH -- mental health, PCS -- physical component summary scores, MCS -- mental component summary scores. Bold values indicate statistically significant differences. P-value1 -- statistically significant difference between low disease activity and moderate disease activity, p-value2 -- statistically significant difference between low disease activity and high disease activity, p-value3 -- statistically significant difference between moderate disease activity and high disease activity.

###### 

Bivariate Pearson correlation analysis of pSS patients between EULAR Sjögren's syndrome outcome measures and MAF, HADS-A, HADS-D snf SF-36 scores

  Parameter   ESSDAI    ESSPRI               
  ----------- --------- ---------- --------- ----------
  PF          --0.435   \< 0.001   --0.336   \< 0.001
  RP          --0.296   0.001      --0.396   \< 0.001
  BP          --0.361   \< 0.001   --0.531   \< 0.001
  GH          --0.328   \< 0.001   --0.687   \< 0.001
  VT          --0.247   \< 0.001   --0.436   \< 0.001
  SF          --0.474   \< 0.001   --0.271   0.002
  RE          --0.484   \< 0.001   --0.347   \< 0.001
  MH          --0.245   0.005      NS        
  PCS         --0.327   \< 0.001   --0.692   \< 0.001
  MCS         --0.502   \< 0.001   --0.263   0.002
  MAF         0.026     0.003      0.805     \< 0.001
  HADS-A      NS                   0.585     \< 0.001
  HADS-D      NS                   0.494     \< 0.001

ESSDAI -- EULAR Sjögren's syndrome disease activity index, ESSPRI -- EULAR Sjögren's syndrome patient reported index, EULAR -- European League Against Rheumatism, MAF -- Multidimensional Assessment of Fatigue, HADS-A -- Hospital Anxiety and Depression Scale-anxiety, HADS-D -- Hospital Anxiety and Depression Scale-depression, PF -- physical functioning, RP -- role-physical, BP -- bodily pain, GH -- general health, VT -- vitality, SF -- social functioning, RE -- role-emotional, MH -- mental health, PCS -- physical component summary scores, MCS -- mental component summary scores, NS -- not significant.

As summarized in [Table V](#t0005){ref-type="table"}, ESSDAI in the pSS group was an independent determinant of all SF-36 scales with the exception of VT. ESSPRI was an independent determinant of BP, GH, MH and PCS. Depression, anxiety, and fatigue were significantly correlated with four or more scales of the SF-36.

###### 

Standard regression coefficients (β) on multiple linear regression analysis for SF-36 scores 

  ------------------------------------------------------------------------------------------------------------------------------------------------------
  Parameter   PF                   RP           BP           GH           VT           SF           RE           MH           PCS           MCS
  ----------- -------------------- ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------- ------------
  HADS-A      --0.753\                                       --0.458\                  --0.718\     --0.529\     --0.967\                   
              (--1.029,\                                     (--0.797,\                (--1.109,\   (--1.140,\   (--1.346,\                 
              --0.477; \< 0.001)                             --0.118;\                 --0.327;\    --0.044;\    --0.588,\                  
                                                             0.009)                    \< 0.001)    0.035)       \< 0.001)                  

  HADS-D                           --0.932\     --0.662\                  --0.607\                  --1.029\                  --0.570\      --0.738\
                                   (--1.486,\   (--1.149,\                (--1.013,\                (--1.729,\                (--0.919,\    (--1.004,\
                                   --0.389;\    --0.175;\                 --0.200;\                 --0.328;\                 --0.221;\     --0.472;\
                                   0.001)       0.008)                    0.004)                    0.004)                    0.002)        \< 0.001)

  MAF                              --0.217\                  --0.273\     --0.256\                                            --0.215\      
                                   (--0.378,\                (--0.441,\   (--0.370,\                                          (--0.358,\    
                                   --0.056;\                 --0.104;\    --0.142;\                                           --0.072;\     
                                   0.009)                    0.002)       \< 0.001)                                           0.004)        

  ESSDAI      --0.505\             --0.381\     --0.394\     --0.210\                  --0.803\     --0.963\     --0.335\     --0.202\      --0.604\
              (--0.701,\           (--0.652,\   (--0.639,\   (--0.410,\                (--1.080,\   (--1.268,\   (--0.565,\   (--0.373,\    (--0.793,\
              --0.309;\            --0.110;\    --0.150;\    --0.009;\                 --0.525;\    --0.658;\    --0.106;\    --0.030;\     --0.415;\
              \< 0.001)            0.006)       0.002)       0.041)                    \< 0.001)    \< 0.001)    0.005)       0.022)        \< 0.001)

  ESSPRI                                        --1.268\     --0.968\                                            0.714\       --0.930\      
                                                (--1.895,\   (--1.718,\                                          (0.091,\     (--1.1558,\   
                                                --0.642;\    --0.217;\                                           1.338;\      --0.301;\     
                                                \< 0.001)    0.012)                                              0.025)       0.004)        
  ------------------------------------------------------------------------------------------------------------------------------------------------------

5% and 95% CI and p-values are presented in parentheses.

Discussion {#sec4}
==========

In order to increase treatment adherence and obtain a better outcome, the evaluation of health quality is important in chronic diseases \[[@cit0027], [@cit0028]\]. The results of this study showed that all domains of the SF-36, particularly RP and role-emotional, were impaired in pSS patients compared with the age- and gender-matched healthy controls. These results are in agreement with previous studies \[[@cit0010], [@cit0013], [@cit0029]--[@cit0036]\]. ESSDAI and ESSPRI outcome measures were significantly correlated with all domains of SF-36 (except MH for ESSPRI) and fatigue. In addition, ESSDAI was positively correlated with anxiety and depression scores. Lendrem *et al.* also reported that higher scores on the ESSDAI and ESSPRI were associated with poorer health states \[[@cit0019]\]. In another study which assessed the quality of life using the SF-36, Cho *et al.* reported that pSS patients with low HRQOL had higher ESSPRI scores and ESSPRI scores were associated with all the SF-36 scales. In contrast to the current study, ESSDAI in that study was not associated with any scales of the SF-36 \[[@cit0020]\].

Fatigue is an important symptom which has been reported to be related to worsening HRQOL in pSS \[[@cit0004], [@cit0006], [@cit0011]\]. In the current study the fatigue score of PSS patients was significantly higher than that of the control group and was positively correlated with anxiety, depression, ESSDAI and ESSPRI scores. Similarly, another study reported that depression was associated with and partially accounted for fatigue in PSS patients \[[@cit0006]\]. In addition, Barendregt *et al.* and Bax *et al.* revealed that depression was the most relevant cause of fatigue in pSS patients \[[@cit0004], [@cit0037]\]. In the current study, fatigue was a significant determinant of RP, GH, VT and PCS scores.

Likewise, the prevalence of depression and anxiety was higher in the pSS group. Previous studies have reported that patients with pSS appear to be at increased risk for clinical depression and anxiety, and this psychological disorder can impair quality of life \[[@cit0005], [@cit0012], [@cit0038], [@cit0039]\]. In the current study, the anxiety score was positively correlated with depression, fatigue and ESSPRI scores. Multivariate linear regression analysis showed that anxiety had a negative impact on PF, GH, SF, RE and MH and depression had a negative impact on RP, BP, VT, RE, PCS and MCS.

Multivariate analyses have revealed that the factors most strongly associated with HRQOL impairment were pain, depression, anxiety, fatigue and ESSPRI \[[@cit0010], [@cit0020], [@cit0036], [@cit0040], [@cit0041]\]. Similarly, in this study, depression, fatigue and ESSDAI were predictors of worse health quality. Unlike other studies, the results of the current study showed that ESSDAI was a predictor for reduced HRQOL \[[@cit0020], [@cit0041]\]. The pSS patients had a higher mean ESSDAI of 6.56 compared to 3.03 in a study by Cho *et al.*, which was unable to provide conclusive information about the impact of systemic activity \[[@cit0020]\].

There were several limitations of this study. No evaluation was made of the effect of socio-economic status, education, the impact of medication, drug compliance, auto-antibodies, salivary gland biopsy score, vaginal dryness of women and objective dryness measurements. Laboratory markers such as HSP90a, which may signal fatigue in chronic inflammation and has no direct effect on the depressive state, may be used to evaluate fatigue objectively \[[@cit0042]\]. Due to the cross-sectional design of the study, the relationship between disease activity, depression, anxiety, fatigue and quality of life remains unclear.

In conclusion, the results of this study showed that the HRQOL of pSS patients was impaired compared to the age- and gender-matched healthy control group and patients with higher disease activity scores had worse HRQOL scores. ESSDAI was negatively correlated with SF-36 scores and positively with MAF. ESSPRI was negatively correlated with SF scores except for mental health and was positively correlated with MAF, HADS-A and HADS-D. Anxiety, depression, fatigue, ESSDAI and ESSPRI were associated with the most SF-36 subscales. Worse quality of life and associated factors should be taken into account when managing patients with pSS. Primary end points for therapeutic trials should include the cardinal primary SS symptoms such as anxiety, depression, and fatigue.
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